Organization

Headquartered in Bethesda, Maryland, Orano USA is a leading technology and services provider for decommissioning shutdown nuclear energy facilities, managing used nuclear fuel, conducting federal site clean-up and closure, and the sale of uranium, conversion, and enrichment services to the U.S. commercial and federal markets. In the nuclear medicine field, Orano Med is developing a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells. https://www.orano.group/usa